TFRC and plasma cell myeloma: Orthogonal delivery was achieved by coating TiO2 with apo-transferrin (Tf) and radiolabeling daratumumab to target transferrin receptors (CD71) and CD38, respectively, which are overexpressed on rapidly proliferating myeloma cells 19.